Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.
Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page
- Check2 days agoChange DetectedThe changes appear to be minor UI updates, including the Last Update timestamp; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check9 days agoChange DetectedAdded a Locations section including Pennsylvania and removed the older Pennsylvania Locations; the HHS Vulnerability Disclosure entry was removed in revision v3.3.3.SummaryDifference0.2%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedNo significant additions or deletions detected; the page content and study details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check31 days agoChange DetectedThe update appears to involve minor user-interface adjustments and a timestamp change on the Study Details page; there are no changes to core study content such as eligibility criteria, outcomes, or study design. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check38 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2; no changes to study content, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check45 days agoChange DetectedRemoved the general notice about government funding and NIH operating status from the ClinicalTrials.gov page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.